Approval · Notice of Compliance 23046 · 2019
RINVOQ: Notice of Compliance 23046
Issued December 23, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23046
- Date
- December 23, 2019
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RINVOQ | 02495155 | Marketed |
Medicinal ingredients
- UPADACITINIB 15 MG per TAB